Clinical characteristics of patients undergoing radiotherapy
| Characteristics | Total (n = 486) | LUAD (n = 226) | LUSC (n = 260) |
|---|---|---|---|
| Gender, n (%) | |||
| Male | 185 (38.07%) | 109 (48.23%) | 192 (73.85%) |
| Female | 301 (61.93%) | 117 (51.77%) | 68 (26.15%) |
| Age, y, n (%) | |||
| < 60 | 103 (21.19%) | 60 (26.55%) | 43 (16.54%) |
| ≥ 60 | 374 (76.96%) | 161 (71.24%) | 213 (81.92%) |
| NA | 9 (1.85%) | 5 (2.21%) | 4 (1.54%) |
| Tumor stage, n (%) | |||
| I | 258 (53.09%) | 133 (58.85%) | 125 (48.08%) |
| II | 135 (27.78%) | 47 (20.80%) | 88 (33.84%) |
| III | 70 (14.40%) | 29 (12.83%) | 41 (15.77%) |
| IV | 16 (3.29%) | 12 (5.31%) | 4 (1.54%) |
| NA | 7 (1.44%) | 5 (2.21%) | 2 (0.77%) |
| NSCLC, n (%) | |||
| LUAD | 226 (46.50%) | 226 (100%) | 0 |
| LUSC | 260 (53.50%) | 0 | 260 (100%) |
| Progression, n (%) | |||
| No | 322 (66.26%) | 135 (59.73%) | 187 (71.92%) |
| Yes | 260 (33.74%) | 91 (40.27%) | 73 (28.08%) |
| Survival, n (%) | |||
| No | 186 (38.27%) | 78 (34.51%) | 108 (41.54%) |
| Yes | 300 (61.73%) | 148 (65.49%) | 152 (58.46%) |